Do you offer immunotherapy for partial loss of MSH6 but MSS stable by PCR in rectal adenocarcinoma?

This is not an uncommon scenario. Often, a formal tumor board discussion with a pathologist explaining the findings can explain if it’s a true mismatch repair deficiency and/or a staining/test issue.

Remember the immunotherapy approval was for mismatch repair deficiency by IHC; it doesn’t need confir...

This is a possible but uncommon (less than 5%) finding with MSI.

We can determine whether it is true or not by investigating the NGS profile and TMB. A blood liquid tumor profile will give that information.

Numerous gene mutations and high TMB would confirm MSI status, and I would then use ICI thera...